<span lang="EN-GB"></span> <font face="Times New Roman" size="3"> </font> <span lang="EN-GB"></span>

 

 

<span lang="EN-GB"></span>

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

  • 02/09/2016 15:11

    PAION discontinues European Remimazolam Phase III Trial in cardiac surgery patients due to insufficient recruitment

  • 02/18/2016 15:11

    PAION reports about positive pre-NDA meeting with Japanese authority PMDA

  • 04/11/2016 15:11

    PAION successfully completes patient recruitment in Phase III study with Remimazolam for procedural sedation during colonoscopy

  • 06/19/2016 15:11

    PAION reports positive remimazolam headline data in pivotal U.S. Phase III study in procedural sedation for colonoscopy

  • 06/24/2016 18:20

    PAION grants Cosmo Pharmaceuticals Remimazolam license in the U.S. and Cosmo becomes largest Shareholder of PAION AG

  • 12/19/2016 19:38

    PAION successfully completes patient recruitment in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy